New hope for aggressive breast cancer: targeted drug tested in organ crisis patients
NCT ID NCT07203729
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tests whether a new drug, Trastuzumab rezetecan (SHR-A1811), works better than standard chemotherapy for people with HER2-Low breast cancer that has spread and is causing severe organ problems (visceral crisis). About 184 adults aged 18-75 will receive the drug every three weeks. The main goal is to see how long the cancer stays under control. This is not a cure, but aims to control the disease and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW UNRESECTABLE/METASTATIC BREAST CANCER COMPLICATED WITH VISCERAL CRISIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.